Q3 2015 13F Holders as of 30 Sep 2015
-
Type / Class
-
Debt / NOTE 1.500%10/1
-
Number of holders
-
40
-
Total 13F principal, excl. options
-
285,934,000
-
Principal change
-
-2,222,524
-
Total reported value, excl. options
-
$385,434,373
-
Value change
-
-$18,978,023
-
Number of buys
-
15
-
Number of sells
-
-15
-
Price
-
$1.34
Significant Holders of BIOMARIN PHARMACEUTICAL INC - NOTE 1.500%10/1 as of Q3 2015
47 filings reported holding 09061GAF8 - BIOMARIN PHARMACEUTICAL INC - NOTE 1.500%10/1 as of Q3 2015.
BIOMARIN PHARMACEUTICAL INC - NOTE 1.500%10/1 has 40 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $285,934,000 of principal
.
Largest 10 bondholders include Invesco Ltd. ($46,021,000 of principal), Calamos Advisors LLC ($35,219,000 of principal), FRANKLIN RESOURCES INC ($29,700,000 of principal), ADVENT CAPITAL MANAGEMENT /DE/ ($22,554,000 of principal), ROYAL BANK OF CANADA ($20,758,000 of principal), Allianz Asset Management AG ($17,235,000 of principal), BlackRock Advisors LLC ($13,855,000 of principal), LORD, ABBETT & CO. LLC ($10,236,000 of principal), BANK OF AMERICA CORP /DE/ ($10,098,000 of principal), and AMERIPRISE FINANCIAL INC ($9,430,000 of principal).
This table shows the top 40 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.